Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€112.50

€112.50

-0.660%
-0.75
-0.660%
€180.00
 
25.07.25 / Tradegate WKN: 659990 / Symbol: MKGAF / Name: Merck / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Merck KGaA Stock

The price for the Merck KGaA stock decreased slightly today. Compared to yesterday there is a change of -€0.750 (-0.660%).
With 9 Buy predictions and not the single Sell prediction the community is currently very high on Merck KGaA.
With a target price of 180 € there is a hugely positive potential of 60.0% for Merck KGaA compared to the current price of 112.5 €.
Our community identified positive and negative aspects for Merck KGaA stock for the coming years. 1 users see the criterium "Return on equity" as a plus for the Merck KGaA stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.

Pros and Cons of Merck KGaA in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Merck KGaA vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Merck KGaA -0.660% 0.897% 1.902% -27.349% -19.152% -37.673% 0.716%
Bayer AG 0.520% 5.929% 11.086% 6.586% 51.269% -49.376% -51.830%
Elanco Animal Health Inc. 0.080% 1.876% 7.712% 7.639% 10.062% -37.064% -37.296%
Johnson & Johnson -0.750% 1.761% 9.705% -2.675% 3.063% -15.012% 12.653%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.

Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.

Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.

Comments

Merck KGaA (OTCMKTS: MKGAF) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Ratings data for MKGAF provided by MarketBeat
Show more

Merck KGaA (OTCMKTS: MKGAF) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Ratings data for MKGAF provided by MarketBeat
Show more

Merck KGaA (OTCMKTS: MKGAF) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Ratings data for MKGAF provided by MarketBeat
Show more

News

Does This Move Make Merck Stock a Buy?: https://g.foolcdn.com/editorial/images/824791/physician-giving-medicine-to-elderly-patient.jpg
Does This Move Make Merck Stock a Buy?

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its

Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business: https://g.foolcdn.com/editorial/images/824726/a-group-of-business-people-talking-outside.jpg
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business

One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating

2 Top Stocks Down 16% and 17% This Year to Buy and Hold: https://g.foolcdn.com/editorial/images/823999/pharmacist-talking-to-patient.jpg
2 Top Stocks Down 16% and 17% This Year to Buy and Hold

Most people love a bargain; investors do too. Purchasing shares of companies that can perform well over long periods is already pretty exciting, but it's even more so when they can be scooped up